Dutch AI Startup Secures €2.3 Million to Prevent Surgical Infections
Netherlands, Tuesday, 14 April 2026.
Netherlands-based Healthplus.ai has raised €2.3 million to expand its revolutionary PERISCOPE® system, which uses artificial intelligence to predict infection risks for individual patients after surgery. The technology can save hospitals up to €4 million annually by reducing postoperative complications and lowering staff workload pressures. Led by Elevating Capital and LUMO Labs, this funding will accelerate European rollout and launch US operations.
MedTech Innovation Targeting Healthcare Efficiency
This represents a significant development in the healthtech sector, specifically focusing on surgical care improvement through artificial intelligence. Healthplus.ai operates as a MedTech scale-up that has developed PERISCOPE®, an AI system designed to predict infection risks on a per-patient basis following surgical procedures [1]. The technology directly addresses postoperative complications, which constitute a major cost center and source of workplace stress in healthcare systems [1]. Dr. Bart Geerts, CEO and founder of Healthplus.ai, leads this Amsterdam-based company that emerged from his observations of how postoperative complications harm patients while creating substantial costs for hospitals [2].
How PERISCOPE® Technology Functions
The PERISCOPE® system operates by calculating infection risks for individual patients after surgery and directly linking these predictions to targeted actions for healthcare teams [1]. This AI-powered approach enables more precise patient stratification, allowing doctors and nurses to create superior treatment plans, intervene more quickly with high-risk patients, and safely discharge low-risk patients earlier [1]. The system integrates seamlessly with Electronic Patient Record (EPD) systems that serve the Dutch and broader European markets, including Epic, Oracle Cerner, and ChipSoft [1]. Crucially, PERISCOPE® features automatic calibration capabilities, ensuring accurate predictions across different types of hospitals while meeting all regulatory requirements [1].
Investment Structure and Strategic Objectives
The €2.3 million funding round was led by Elevating Capital and LUMO Labs, with participation from Pathena Venture Capital, Leistone (Renza Family), and ROM InWest [1]. This late seed-stage investment strengthens Healthplus.ai’s capacity to integrate clinically validated, regulatory-approved AI into daily hospital practice [1]. The company plans to deploy this capital to accelerate European expansion while initiating operations in the United States market [1]. Additionally, funds will support continued development of AI risk models covering all phases of surgical procedures [1].
Regional Impact and Market Positioning
Sara Schaafsma, Investment Manager at ROM InWest, emphasized the technology’s potential to help patients recover faster, make specialists’ work more efficient, and reduce strain on healthcare systems [1]. Healthplus.ai exemplifies the innovation capabilities of Noord-Holland, which maintains an impressive ecosystem in Life Sciences & Health and AI, featuring research institutions, educational programs, campuses, startups, hospitals, and top-tier investors [1]. This ecosystem demonstrates international competitiveness and increasing visibility, with ROM InWest collaborating with Amsterdam knowledge institutions to organize and lead regional cooperation efforts [1]. The company represents a combination of Amsterdam’s European-leading AI expertise with clinical healthcare innovation, positioning the region to achieve international breakthrough success in the intersection of world-class AI and Life Sciences & Health [1].